http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#Head http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#assertion http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#provenance http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#pubinfo http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#assertion http://purl.obolibrary.org/obo/DOID_7147 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_7147 http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB06674 http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#association http://www.w3.org/2000/01/rdf-schema#label simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 1 1 active psoriatic arthritis psa alone or in combination with methotrexate 1 2 active ankylosing spondylitis as 1 3 moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 1 4 inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders simponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis simponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritis simponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6 mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 14 4 http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB06674 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#provenance http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#pubinfo http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#sig http://purl.org/nanopub/x/hasSignature g9eGDLmPAbbWnXSNLRE1YPVbuzhMSrbrQ7xWL4TGXRNwarhTjnSz26bL/YUyZ0YH/x2yfK0Ho9vctEc6v+qwLj+EW3VKHI9FRsb1P/Da524Pj0qSk0LmFu/ALXJniHyrwqGnHiJvsPcwYXJiuQYYbR88zqvmlDI+FrURA8JGeO8= http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc http://purl.org/dc/terms/created 2021-07-03T15:03:11.309+02:00 http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RACgHM6Unm5Ui8rLfTQSbFMonw_sJtK_bg1Eb90QpBbEc https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs